Omali Pitiyarachchi, Medical oncologist at the Lost Cancer Research Centre at UNSW Sydney, shared a post on X:
“Great to see further advances in the treatment of ovarian cancer at ASCOBT26.
Interim analysis rezatapopt monotherapy, targeted activity in heavily preRx pts TP53 Y220C-mt advanced OC, ORR 44%, mDoR 8.2 mo, safety profile seems ok, prior bev use in 80%.”
Other articles about Ovarian Cancer on OncoDaily.
